Stay updated with breaking news from Lekhram Changoer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has added 22 new clinical and pre-clinical research projects through the acquisition of APIRx Pharmaceuticals...
Advancements for Anxiety, Sleep Apnea, Brain Injury, Lung Inflammation, Rheumatoid Arthritis & Inflammatory Bowel Disease : Incannex Healthcare Limited
The acquisition of APIRx will significantly strengthen Incannex's position with regard to cannabinoid and psychedelic treatment development.
Incannex Healthcare (ASX: IHL) has announced it will acquire APIRx Pharmaceutical USA in an all scrip (share consideration) deal to affirm its position as a global leader in the fields of cannabinoid, psychedelic and combination pharmaceuticals.
Highlights: APIRx has twenty-two (22) active clinical and pre-clinical research and development projects therapeutic candidates are targeted at treating pain,...